UgeneX Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
UgeneX Therapeutics - overview
Established
2021
Location
Suzhou, Jiangsu, China
Primary Industry
Biotechnology
About
Based in Suzhou, China and founded in 2021, UgeneX Therapeutics is a developer of ophthalmic drugs, focusing on the development of drugs for the treatment of ophthalmic diseases. The founder and chief scientific officer, Dr. Hongjun Liu, he graduated from San Diego State University, he is expert in the field of retinal nerve cell regeneration. In August 2021, the company raised angel funding from Shanghai Fosun Pharmaceutical (Group).
The company's new gene therapy strategy is to use other nerve cell types in the patient's retina to regenerate missing nerve cells. It can also be used in other parts of the nervous system, which is expected to treat other nervous system diseases.
Current Investors
Shanghai Fosun Pharmaceutical (Group)
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.